GB9109862D0
(en)
*
|
1991-05-08 |
1991-07-03 |
Beecham Lab Sa |
Pharmaceutical formulations
|
GB9416600D0
(en)
|
1994-08-17 |
1994-10-12 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
GB9416599D0
(en)
*
|
1994-08-17 |
1994-10-12 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
ES2079327B1
(en)
*
|
1994-12-13 |
1996-08-01 |
Lilly Sa |
PHARMACEUTICAL FORMULATIONS OF CEFACLOR.
|
GB9501127D0
(en)
*
|
1995-01-20 |
1995-03-08 |
Wellcome Found |
Tablet
|
US20030109503A1
(en)
*
|
1995-06-06 |
2003-06-12 |
Smithkline Beecham P.L.C. |
Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
|
JPH11510811A
(en)
*
|
1995-08-12 |
1999-09-21 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
Pharmaceutical prescription
|
DK0862431T3
(en)
|
1995-09-07 |
2002-03-11 |
Smithkline Beecham Plc |
Use of pediatric pharmaceutical formulation comprising amoxycillin and clavulanate
|
TW473393B
(en)
*
|
1996-02-29 |
2002-01-21 |
Fujisawa Pharmaceutical Co |
Beta-lactam antibiotic-containing tablet and production thereof
|
TWI225402B
(en)
*
|
1996-03-13 |
2004-12-21 |
Biochemie Gmbh |
Auxiliary-free agglomerates
|
AT407701B
(en)
*
|
1996-08-12 |
2001-05-25 |
Biochemie Gmbh |
Mixture which is suitable for direct tableting and contains as essential components amoxicillin trihydrate and the calcium salt of clavulanic acid, and process for preparing this mixture
|
US6893664B1
(en)
|
1996-06-17 |
2005-05-17 |
Powderject Research Limited |
Particle delivery techniques
|
US5837292A
(en)
*
|
1996-07-03 |
1998-11-17 |
Yamanouchi Europe B.V. |
Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
|
GB9616536D0
(en)
|
1996-08-06 |
1996-09-25 |
Quadrant Holdings Cambridge |
Co-amoxiclav dosage form
|
AU6496498A
(en)
*
|
1997-02-07 |
1998-08-26 |
Gist-Brocades B.V. |
Homogeneous granulated formulations for dose sipping technology
|
KR100499812B1
(en)
*
|
1997-02-14 |
2005-07-08 |
스미스클라인 비참 코포레이션 |
Pharmaceutical formulation comprising amoxycillin and clavulanate
|
US20030124187A1
(en)
*
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
WO1999011261A1
(en)
*
|
1997-08-29 |
1999-03-11 |
Dsm N.V. |
Granules free of excipients
|
DE19820801A1
(en)
*
|
1998-05-09 |
1999-11-25 |
Gruenenthal Gmbh |
Oral dosage form for gatifloxacin, providing reproducible decomposition time and drug release
|
US6177421B1
(en)
|
1999-05-04 |
2001-01-23 |
Fuisz International Ltd. |
Amoxicillin and clavulanate composition
|
AU1232500A
(en)
*
|
1998-10-30 |
2000-05-22 |
Fuisz International Ltd. |
Improved amoxycillin and clavulanate composition
|
IE990159A1
(en)
*
|
1999-02-26 |
2000-09-20 |
Fuisz Internat Ltd |
Storage Stable Amoxycillin and Clavulanate Suspension Composition.
|
US6979735B1
(en)
|
1999-04-01 |
2005-12-27 |
Dsm N.V. |
Agglomerates by crystallization
|
US7250176B1
(en)
|
1999-04-13 |
2007-07-31 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection
|
NZ514575A
(en)
*
|
1999-04-13 |
2004-05-28 |
Beecham Pharm Pte Ltd |
Novel method of treatment
|
US6294199B1
(en)
|
1999-04-13 |
2001-09-25 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising administering amoxycillin
|
US6878386B1
(en)
|
1999-04-13 |
2005-04-12 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
|
US20020006433A1
(en)
*
|
1999-04-29 |
2002-01-17 |
Nigel P. Davidson |
Pharmaceutical formulations
|
GB9930578D0
(en)
*
|
1999-12-23 |
2000-02-16 |
Smithkline Beecham Plc |
Pharmaceutical formulations
|
US6565882B2
(en)
*
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US6544555B2
(en)
*
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6756057B2
(en)
|
2000-10-12 |
2004-06-29 |
Beecham Pharmaceuticals (Pte) Limited |
Amoxicillin and potassium clavulanate dosage form
|
AU2001292185A1
(en)
|
2000-10-12 |
2002-04-22 |
Beecham Pharmaceuticals (Pte) Limited |
Formulation containing amoxicillin
|
US6541014B2
(en)
*
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
WO2002032906A1
(en)
*
|
2000-10-20 |
2002-04-25 |
Biochemie Gesellschaft M.B.H. |
Pharmaceutical compositions
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
US6720000B2
(en)
|
2001-03-19 |
2004-04-13 |
Three Rivers Pharmaceutical, Llc |
Process for producing wet ribavirin pellets
|
AT413983B
(en)
*
|
2001-04-12 |
2006-08-15 |
Sandoz Ag |
Pharmaceutical composition useful for reducing rapid degradation of the active ingredient comprises clavulanate, in the form of granulated and hydrophobised particles, and an active ingredient
|
AT412344B
(en)
*
|
2001-04-12 |
2005-01-25 |
Sandoz Ag |
Pharmaceutical composition useful for reducing rapid degradation of the active ingredient comprises clavulanate, in the form of granulated and hydrophobised particles, and an active ingredient
|
WO2003086343A2
(en)
*
|
2002-04-05 |
2003-10-23 |
Cadila Healthcare Limited |
Fast disintegrating oral dosage forms
|
EP1539146A1
(en)
*
|
2002-07-16 |
2005-06-15 |
Ranbaxy Laboratories, Ltd. |
Dispersible tablets for oral administration
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7538094B2
(en)
|
2002-09-19 |
2009-05-26 |
Three Rivers Pharmacueticals, Llc |
Composition containing ribavirin and use thereof
|
CA2406592C
(en)
*
|
2002-10-04 |
2003-09-30 |
Duchesnay Inc. |
Method of preparing pharmaceutical dosage forms containing multiple active ingredients
|
AU2004258953B2
(en)
*
|
2003-07-21 |
2011-02-10 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
CA2533178C
(en)
*
|
2003-07-21 |
2014-03-11 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
EP1648418A4
(en)
*
|
2003-07-21 |
2011-11-16 |
Middlebrook Pharmaceuticals Inc |
Antibiotic product, use and formulation thereof
|
FR2858556B1
(en)
*
|
2003-08-06 |
2006-03-10 |
Galenix Innovations |
DISPERSIBLE AND / OR ORODISPERSIBLE SOLID PHARMACEUTICAL COMPOSITION, NOT PELLETIZED, CONTAINING AT LEAST THE METFORMIN ACTIVE INGREDIENT, AND PROCESS FOR PREPARING THE SAME
|
JP2007502296A
(en)
|
2003-08-11 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
Robust pellet
|
WO2005016278A2
(en)
*
|
2003-08-12 |
2005-02-24 |
Advancis Pharmaceuticals Corporation |
Antibiotic product, use and formulation thereof
|
US20050089502A1
(en)
*
|
2003-08-21 |
2005-04-28 |
Todd Schansberg |
Effervescent delivery system
|
WO2005023184A2
(en)
*
|
2003-08-29 |
2005-03-17 |
Advancis Pharmaceuticals Corporation |
Antibiotic product, use and formulation thereof
|
WO2005027877A1
(en)
*
|
2003-09-15 |
2005-03-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
EP1686963A1
(en)
*
|
2003-10-27 |
2006-08-09 |
PSivida Inc. |
Suspension delivery system for the sustained and controlled local release of pharmaceuticals
|
WO2005062898A2
(en)
*
|
2003-12-24 |
2005-07-14 |
Advancis Pharmaceutical Corporation |
Enhanced absorption of modified release dosage forms
|
JP2007523125A
(en)
*
|
2004-02-24 |
2007-08-16 |
サンド・アクチエンゲゼルシヤフト |
Amoxicillin instant granules
|
CN1767818A
(en)
*
|
2004-05-31 |
2006-05-03 |
三亚药品株式会社 |
Dispersible tablet comprising beta lactam antibiotics and process for preparing the same
|
JP2008505124A
(en)
*
|
2004-07-02 |
2008-02-21 |
アドバンシス ファーマスーティカル コーポレイション |
Pulse delivery tablets
|
DE102004054054A1
(en)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
|
EA012421B1
(en)
|
2005-03-03 |
2009-10-30 |
Янссен Фармацевтика Н. В. |
Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
|
DE602006016244D1
(en)
|
2005-03-08 |
2010-09-30 |
Janssen Pharmaceutica Nv |
DIAZASPIRO Ä4,4Ü NONANDERIVATES AS NEUROKININ (NK1) ANTAGONISTS
|
WO2007058397A1
(en)
*
|
2005-11-17 |
2007-05-24 |
Gl Pharmtech Corp. |
A dispersible tablet comprising the mixture of amoxicillin and clavulanic acid or its salts and processes for preparing the same
|
US8778924B2
(en)
*
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
CN103951667A
(en)
|
2006-05-04 |
2014-07-30 |
勃林格殷格翰国际有限公司 |
Polymorphs
|
PE20080251A1
(en)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
USES OF DPP IV INHIBITORS
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
CA2563690C
(en)
*
|
2006-10-12 |
2014-10-07 |
Pharmascience Inc. |
Pharmaceutical compositions comprising intra- and extra- granular fractions
|
FI20070521L
(en)
|
2006-11-10 |
2008-05-11 |
Atacama Labs Oy |
Grains, tablets and granulation process
|
US8951562B2
(en)
|
2006-11-10 |
2015-02-10 |
Atacama Labs Oy |
Method and apparatus or dry granulation
|
DK3150586T3
(en)
|
2007-02-23 |
2020-02-17 |
Gilead Sciences Inc |
MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
|
MX2010004556A
(en)
|
2007-10-26 |
2010-07-01 |
Rexahn Pharmaceuticals Inc |
Pharmaceutical formulation of clavulanic acid.
|
PE20140960A1
(en)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
FORMULATIONS INVOLVING A DPP4 INHIBITOR
|
PL2296633T3
(en)
|
2008-05-02 |
2016-03-31 |
Gilead Sciences Inc |
The use of solid carrier particles to improve the processability of a pharmaceutical agent
|
EP2291233B1
(en)
|
2008-05-09 |
2019-09-04 |
Atacama Labs Oy |
Method for dry granulation
|
KR20200118243A
(en)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment for diabetes in patients inappropriate for metformin therapy
|
UY32030A
(en)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
TW201028168A
(en)
*
|
2008-12-19 |
2010-08-01 |
Solvay Pharm Bv |
Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability
|
MX2011006713A
(en)
|
2008-12-23 |
2011-07-13 |
Boehringer Ingelheim Int |
Salt forms of organic compound.
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
KR101835893B1
(en)
*
|
2009-10-26 |
2018-04-19 |
머크 샤프 앤드 돔 코포레이션 |
Solid pharmaceutical compositions containing an integrase inhibitor
|
KR20230021159A
(en)
|
2009-11-27 |
2023-02-13 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
WO2011080502A2
(en)
|
2009-12-29 |
2011-07-07 |
Orexo Ab |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
EP2519229A2
(en)
|
2009-12-29 |
2012-11-07 |
Novartis AG |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
KR20130069615A
(en)
*
|
2010-05-05 |
2013-06-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
Pharmaceutical formulations comprising pioglitazone and linagliptin
|
CN102946875A
(en)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
Combination therapy
|
WO2011161161A1
(en)
|
2010-06-24 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
Diabetes therapy
|
US20170087134A1
(en)
*
|
2010-07-12 |
2017-03-30 |
Salix Pharmaceuticals, Ltd |
Formulations of rifaximin and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
HUE043540T2
(en)
|
2011-07-15 |
2019-08-28 |
Boehringer Ingelheim Int |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
JP6224084B2
(en)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Xanthine derivatives as DPP-4 inhibitors for the treatment of glomerular epithelial cell related disorders and / or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
EP2882423A1
(en)
*
|
2012-08-07 |
2015-06-17 |
Sandoz AG |
Uncoated tablet comprising granules including a -lactam antibiotic and highly dispersed silicone dioxide
|
JP2014079286A
(en)
*
|
2012-10-12 |
2014-05-08 |
Hiroaki Koga |
Container containing antimicrobial agent
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
CN109310697A
(en)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
The combination of Li Gelieting and melbine
|
JP7027412B2
(en)
|
2016-09-30 |
2022-03-01 |
サリックス ファーマスーティカルズ,インコーポレーテッド |
Morphology of solid dispersion of rifaximin
|
FI3528791T3
(en)
*
|
2016-10-24 |
2024-01-30 |
Janssen Sciences Ireland Unlimited Co |
Dispersible compositions
|